OpenAlex
PricingAboutJobs
Log inGet started
Work

Disease-modifying treatment does not influence severity and recovery of the first relapse after treatment onset in RRMS: insights from four large-scale clinical trials

HTML

Year: 2026
Type: article
Source: Multiple Sclerosis Journal
DOI: 10.1177/13524585261502632
Authors: Marcus Koch, Jop Mostert, Eva Strijbis, Miguel D’Haeseleer, Øivind Torkildsen, Ester Moral, Luis Brieva, Jacynthe Comtois, Pavle Repovic, Tarrant McPherson, Gary Cutter
Institutions: University of Calgary, Rijnstate Hospital, Amsterdam UMC, Amsterdam UMC Location Vrije Universiteit Amsterdam, Universitair Ziekenhuis Brussel, National MS Center Melsbroek, Haukeland University Hospital, University of Bergen, Hospital de Sant Joan Despí Moisès Broggi, Hospital Universitari Arnau de Vilanova, Université de Montréal, Emory University, University of Alabama at Birmingham
Language: English

Topic: Multiple Sclerosis Research Studies
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Keywords: relapsing-remitting multiple sclerosis, disease-modifying therapy, relapse severity, first relapse, Expanded Disability Status Scale, corticosteroid therapy, interferon, T2 lesion volume, contrast-enhancing lesions, annualized relapse rate
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W7236798964
FWCI:
Cites: 11
Cited by:
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security